Novo Nordisk A/S
MIC-1 AND GLP-1 FOR USE IN THE TREATMENT OF OBESITY
Last updated:
Abstract:
The invention relates to MIC-1 compounds for use in the prevention and/or treatment of obesity, wherein the MIC-1 compounds is administered simultaneously, separately or sequentially with a GLP-1 compound.
Status:
Application
Type:
Utility
Filling date:
10 Sep 2018
Issue date:
25 Jun 2020